Shilpa Medicare Limited has informed the Exchange about USFDA Inspection at Unit VI, Dabaspet, Bengaluru
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
USFDA conducted a Pre-Approval Inspection (PAI) at Shilpa Medicare's Unit VI facility in Dabaspet, Bengaluru from 25 May 2026 to 29 May 2026. The inspection concluded with the issuance of FDA Form 483 containing 5 procedural observations. Importantly, none of these observations are repeat observations nor are they related to data integrity concerns. The facility manufactures oral dispersible films and transdermal patches. Unit VI has a strong compliance track record, holding Voluntary Action Indicated (VAI) status from a previous USFDA GMP inspection, along with accreditations from EMA, SFDA, MHRA, and TGA. The company will submit a comprehensive response to address each observation within the stipulated timeline.
The company states it does not expect any material impact on current business operations or existing supplies. However, investors should monitor whether the FDA accepts the company's corrective response, as unresolved observations could affect future product approvals.